Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
17 participants
INTERVENTIONAL
2014-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The hypothesis is that aminoacid infusion can attenuate the increase in proteindegradation that follows cirrhosis.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of Dietary Assessment and Intervention on Outcomes in Liver Cirrhosis Patients
NCT05259930
HMB Enriched Amino Acids to Reverse Muscle Loss in Cirrhosis
NCT05166499
Treatment of Sarcopenia Improves the Muscle Mass and Muscle Strength of Patients With Liver Cirrhosis-Child C
NCT03633279
Branched Chain Aminoacid Supplementation in Patients With Liver Cirrhosis
NCT02023229
Characterization of the Nutritional Status in the Patient With Liver Cirrhosis
NCT04073693
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Healthy controls
Amino acid infusion
Amino acid infusion
Bloodsamples, Biopsies.
Cirrhosis
Amino acid infusion
Amino acid infusion
Bloodsamples, Biopsies.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Amino acid infusion
Bloodsamples, Biopsies.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of cirrhosis, Child-Pugh A, B, C.
Exclusion Criteria
* Ascites collections within 10 days
* Heart-, kidney, pulmonary disease. Cancer. Type 1 diabetes.
* Active alkoholdrinking
30 Years
70 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hvidovre University Hospital
OTHER
Rigshospitalet, Denmark
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Anders Rasmussen Rinnov
MD, PhD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rigshospitalet
Copenhagen, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H-4-2012-162
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.